Login to Your Account



Medivir, GSK Agree To EUR86M Deal For Phase I HIV Candidate

By Cormac Sheridan


Wednesday, May 28, 2003
Medivir AB entered its largest drug development deal to date, a pact worth up to €86 million with GlaxoSmithKline plc to develop its HIV drug MIV-210. The news sent the Huddinge, Sweden-based company's share price soaring by almost 50 percent during trading on the Stockholm Stock Exchange last week, to close at SEK61 Friday. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription